Summary of Clinical Use

Avdoralimab (IPH5401) has advanced to clinical evaluation as an addition to cancer immunotherapy and for autoimmune diseases. SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, avdoralimab was entered into clinical trial, with the purpose of determining potential efficacy of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in COVID-19 patients [2].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04371367	Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )	Phase 2 Interventional	Assistance Publique Hopitaux De Marseille
NCT04563923	Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody	Phase 2 Interventional	Centre Hospitalier Universitaire de Nice
NCT03665129	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors	Phase 1 Interventional	Innate Pharma	In combination with the anti-PD-L1 immune checkpoint anti-cancer agent .
NCT01611688	First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis	Phase 1 Interventional	Novo Nordisk A/S
NCT01955603	A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis	Phase 1 Interventional	Novo Nordisk A/S